|
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb (Inst) |
Travel, Accommodations, Expenses - Amgen; Ipsen; Novartis; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; MSD; Novartis; Roche; SERVIER |
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Accuray; Accuray; Kyowa Hakko Kirin |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Roche |
Speakers' Bureau - Amgen; Pierre Fabre; Sanofi; Servier |
Travel, Accommodations, Expenses - Merck Serono; Roche; Servier |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
Nathalie Bonichon-Lamichhane |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Celgene; Halozyme; Merck; Roche; SERVIER |
Travel, Accommodations, Expenses - Merck; Roche |
|
|
No Relationships to Disclose |
|
Christelle De La Fouchardiere |
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Lilly; Pierre Fabre; Roche; SERVIER; Shire |
|
Travel, Accommodations, Expenses - Amgen; Amgen; Bristol-Myers Squibb; Celgene; Roche; Roche; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - MSD; Pierre Fabre; Roche; SERVIER |
|
Travel, Accommodations, Expenses - Amgen; Bayer; MSD |